Literature DB >> 24161793

Assessment of the role in protection and pathogenesis of the Chlamydia muridarum V-type ATP synthase subunit A (AtpA) (TC0582).

Chunmei Cheng1, Pooja Jain1, Sukumar Pal1, Delia Tifrea1, Guifeng Sun1, Andy A Teng2, Xiaowu Liang2, Philip L Felgner2,3, Luis M de la Maza1.   

Abstract

A novel Chlamydia muridarum antigen (TC0582) was used to vaccinate BALB/c mice. Mice were also immunized with other components of the ATP synthase complex (TC0580, TC0581, and TC0584), or with the major outer membrane protein (MOMP). TC0582 was also formulated in combination with TC0580, TC0581 or MOMP. TC0582 alone, or in combination with the other antigens, elicited strong Chlamydia-specific humoral and cellular immune responses. Vaccinated animals were challenged intranasally and the course of the infection was followed for 10 days. Based on percentage change in body weight, lung weight, and number of Chlamydia inclusion forming units recovered from the lungs, mice immunized with TC0582, TC0581 or MOMP, as single antigens, showed significant protection. Mice immunized with combinations of two antigens were also protected but the level of protection was not additive. TC0582 has sequence homology with the eukaryotic ATP synthase subunit A (AtpA). Therefore, to determine if immunization with TC0582, or with Chlamydia, elicited antibodies that cross-reacted with the mouse AtpA, the two proteins were printed on a microarray. Sera from mice immunized with TC0582 and/or live Chlamydia, strongly reacted with TC0582 but did not recognize the mouse AtpA. In conclusion, TC0582 may be considered as a Chlamydia vaccine candidate.
Copyright © 2013 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  ATP synthase subunit A; Chlamydia; Immunization; Mice; Vaccine

Mesh:

Substances:

Year:  2013        PMID: 24161793      PMCID: PMC3946604          DOI: 10.1016/j.micinf.2013.10.012

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  46 in total

Review 1.  Chlamydia vaccines: strategies and status.

Authors:  Joseph U Igietseme; Carolyn M Black; Harlan D Caldwell
Journal:  BioDrugs       Date:  2002       Impact factor: 5.807

2.  Trachoma vaccine studies in monkeys.

Authors:  S P Wang; J T Grayston; E R Alexander
Journal:  Am J Ophthalmol       Date:  1967-05       Impact factor: 5.258

Review 3.  The purification of eukaryotic polypeptides synthesized in Escherichia coli.

Authors:  F A Marston
Journal:  Biochem J       Date:  1986-11-15       Impact factor: 3.857

Review 4.  New knowledge of chlamydiae and the diseases they cause.

Authors:  J T Grayston; S Wang
Journal:  J Infect Dis       Date:  1975-07       Impact factor: 5.226

5.  Resolution of secondary Chlamydia trachomatis genital tract infection in immune mice with depletion of both CD4+ and CD8+ T cells.

Authors:  S G Morrison; R P Morrison
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

6.  Vaccination with the recombinant major outer membrane protein elicits antibodies to the constant domains and induces cross-serovar protection against intranasal challenge with Chlamydia trachomatis.

Authors:  Delia F Tifrea; Pooja Ralli-Jain; Sukumar Pal; Luis M de la Maza
Journal:  Infect Immun       Date:  2013-03-11       Impact factor: 3.441

7.  Prevalence of chlamydial and gonococcal infections among young adults in the United States.

Authors:  William C Miller; Carol A Ford; Martina Morris; Mark S Handcock; John L Schmitz; Marcia M Hobbs; Myron S Cohen; Kathleen Mullan Harris; J Richard Udry
Journal:  JAMA       Date:  2004-05-12       Impact factor: 56.272

Review 8.  Vaccines for Chlamydia trachomatis infections.

Authors:  Luis M de la Maza; Ellena M Peterson
Journal:  Curr Opin Investig Drugs       Date:  2002-07

9.  Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis.

Authors:  H D Caldwell; J Kromhout; J Schachter
Journal:  Infect Immun       Date:  1981-03       Impact factor: 3.441

10.  Purification and partial characterization of the opacity-associated proteins of Neisseria gonorrhoeae.

Authors:  M S Blake; E C Gotschlich
Journal:  J Exp Med       Date:  1984-02-01       Impact factor: 14.307

View more
  5 in total

1.  Protection against a chlamydial respiratory challenge by a chimeric vaccine formulated with the Chlamydia muridarum major outer membrane protein variable domains using the Neisseria lactamica porin B as a scaffold.

Authors:  Delia F Tifrea; Sukumar Pal; Jeff Fairman; Paola Massari; Luis M de la Maza
Journal:  NPJ Vaccines       Date:  2020-05-08       Impact factor: 7.344

Review 2.  Update on Chlamydia trachomatis Vaccinology.

Authors:  Luis M de la Maza; Guangming Zhong; Robert C Brunham
Journal:  Clin Vaccine Immunol       Date:  2017-04-05

3.  Computational modeling of TC0583 as a putative component of the Chlamydia muridarum V-type ATP synthase complex and assessment of its protective capabilities as a vaccine antigen.

Authors:  Delia F Tifrea; Michael L Barta; Sukumar Pal; P Scott Hefty; Luis M de la Maza
Journal:  Microbes Infect       Date:  2015-12-17       Impact factor: 2.700

4.  Seroprevalence of antibodies against Pkn1, a novel potential immunogen, in Chlamydia trachomatis-infected Macaca nemestrina and human patients.

Authors:  Achchhe L Patel; Prashant K Mishra; Divya Sachdev; Uma Chaudhary; Dorothy L Patton; Daman Saluja
Journal:  Biomed Res Int       Date:  2014-06-18       Impact factor: 3.411

5.  Protection against a chlamydial respiratory challenge by a chimeric vaccine formulated with the Chlamydia muridarum major outer membrane protein variable domains using the Neisseria lactamica porin B as a scaffold.

Authors:  Delia F Tifrea; Sukumar Pal; Jeff Fairman; Paola Massari; Luis M de la Maza
Journal:  NPJ Vaccines       Date:  2020-05-08       Impact factor: 7.344

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.